New Drugs Approved
New drugs approved since October 2005
- Psychiatry & Neurology Area
- Cardiovascular/ Diabetes Area
- Cancer and Infectious Diseases Area
- Regenerative Medicine/Cell Therapy
- Other Areas
*Approved in the U.S.
Psychiatry & Neurology Area
Product name | Indication | New drugs approved | Launched |
---|---|---|---|
KYNMOBI® (apomorphine HCl)* | OFF episodes associated with Parkinson's disease | May 2020 | Sep. 2020 |
APTIOM® (eslicarbazepine acetate)* | Epilepsy | Nov. 2013 | Apr. 2014 |
LATUDA® (lurasidone hydrochloride)* | Schizophrenia, Bipolar l depression | Oct. 2010 | Feb. 2011 |
TRERIEF® (zonisamide) | Parkinson’s disease | Jan. 2009 | Mar. 2009 |
LONASEN® (blonanserin) | Schizophrenia | Jan. 2008 | Apr. 2008 |
Cardiovascular/ Diabetes Area
Product name | Indication | New drugs approved | Launched |
---|---|---|---|
TWYMEEG® (imeglimin) | Type 2 diabetes | Jun. 2021 | Sep. 2021 |
AIMIX® (amlodipine besilate / irbesartan) | Hypertension / Combination tablets | Sep. 2012 | Dec. 2012 |
SUREPOST® (repaglinide) | The reduction of postprandial blood glucose in patients with type 2 diabetes | Jan. 2011 | May 2011 |
METGLUCO® (metformin hydrochloride) | Type 2 diabetes | Jan. 2010 | Apr. 2010 |
AVAPRO® (irbesartan) | Hypertension | Apr. 2008 | Jun. 2008 |
Cancer and Infectious Diseases Area
Product name | Indication | New drugs approved | Launched |
---|---|---|---|
ORGOVYX® (relugolix)* | Prostate cancer | Dec. 2020 | Jan. 2021 |
RETHIO® (thiotepa) | Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) for pediatric solid tumors | Mar. 2019 | May 2019 |
MIRIPLA® (miriplatin hydrate) | Lipiodolization in hepatocellular carcinoma | Oct. 2009 | Dec. 2009 |
AmBisome® (amphotericin B) | Systemic fungal infection, febrile neutropenia suspected to be caused by fungal infection, visceral leishmaniasis | Apr. 2006 | Jun. 2006 |
Regenerative Medicine/Cell Therapy
Product name | Indication | New drugs approved | Launched |
---|---|---|---|
RETHYMIC® (allogeneic processed thymus tissue-agdc)* | Pediatric congenital athymia | Oct. 2021 | Mar. 2022 |
Other Areas
Product name | Indication | New drugs approved | Launched |
---|---|---|---|
MYFEMBREE® (relugolix combination tablet)* | Uterine fibroids | May 2021 | Jun. 2021 |
GEMTESA® (vibegron)* | Overactive bladder (OAB) | Dec. 2020 | Apr. 2021 |
LONHALA® MAGNAIR® (glycopyrronium bromide)* | Chronic obstructive pulmonary disease (COPD) | Dec. 2017 | Apr. 2018 |